> top > docs > PMC:7205724 > spans > 684-859 > annotations

PMC:7205724 / 684-859 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
55 9-15 Species denotes humans Tax:9606
56 100-108 Species denotes patients Tax:9606
57 166-175 Species denotes SARS-CoV2 Tax:2697049
67 78-86 Disease denotes COVID-19 MESH:C000657245
68 124-132 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T2 88-94 Body_part denotes Plasma http://purl.org/sig/ont/fma/fma62970

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T8 78-86 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 124-132 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 166-170 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T2 9-15 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T3 88-94 http://purl.obolibrary.org/obo/UBERON_0001969 denotes Plasma

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T8 9-15 Species denotes humans NCBItxid:9605
T9 78-86 Species denotes COVID-19 NCBItxid:2697049
T10 124-132 Species denotes COVID-19 NCBItxid:2697049
T11 166-175 Species denotes SARS-CoV2 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T12 17-87 Sentence denotes Here, we will provide an overview of therapeutic options for COVID-19.

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
55 9-15 Species denotes humans Tax:9606
67 78-86 Disease denotes COVID-19 MESH:C000657245
56 100-108 Species denotes patients Tax:9606
68 124-132 Disease denotes COVID-19 MESH:C000657245
57 166-175 Species denotes SARS-CoV2 Tax:2697049

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T106 4-5 -COMMA- denotes ,
T107 6-8 IN denotes in
T108 9-15 NNS denotes humans
T109 17-21 RB denotes Here
T110 21-22 -COMMA- denotes ,
T111 23-25 PRP denotes we
T112 26-30 MD denotes will
T113 31-38 VB denotes provide
T114 39-41 DT denotes an
T115 42-50 NN denotes overview
T116 51-53 IN denotes of
T117 54-65 JJ denotes therapeutic
T118 66-73 NNS denotes options
T119 74-77 IN denotes for
T120 78-86 NN denotes COVID-19
T121 88-94 NN denotes Plasma
T122 95-99 IN denotes from
T123 100-108 NNS denotes patients
T124 109-118 VBN denotes recovered
T125 119-123 IN denotes from
T126 124-132 NN denotes COVID-19
T127 133-137 WDT denotes that
T128 138-146 VBZ denotes contains
T129 147-157 NNS denotes antibodies
T130 158-165 IN denotes against
T131 166-175 NN denotes SARS-CoV2
R101 T108 T107 arg2Of humans,in
R102 T113 T109 arg1Of provide,Here
R103 T113 T110 arg1Of provide,","
R104 T111 T112 arg1Of we,will
R105 T113 T112 arg2Of provide,will
R106 T111 T113 arg1Of we,provide
R107 T115 T113 arg2Of overview,provide
R108 T115 T114 arg1Of overview,an
R109 T115 T116 arg1Of overview,of
R110 T118 T116 arg2Of options,of
R111 T118 T117 arg1Of options,therapeutic
R112 T115 T119 arg1Of overview,for
R113 T120 T119 arg2Of COVID-19,for
R114 T121 T122 arg1Of Plasma,from
R115 T123 T122 arg2Of patients,from
R116 T123 T124 arg2Of patients,recovered
R117 T124 T125 arg1Of recovered,from
R118 T126 T125 arg2Of COVID-19,from
R119 T126 T127 arg1Of COVID-19,that
R120 T126 T128 arg1Of COVID-19,contains
R121 T129 T128 arg2Of antibodies,contains
R122 T129 T130 arg1Of antibodies,against
R123 T131 T130 arg2Of SARS-CoV2,against

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T2 88-94 Body_part denotes Plasma http://purl.org/sig/ont/fma/fma62970

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T8 78-86 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 124-132 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 166-175 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T12 17-87 Sentence denotes Here, we will provide an overview of therapeutic options for COVID-19.